Revenue Recognition (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended				9 Months Ended		12 Months Ended
	Oct. 31, 2022	Jul. 31, 2021	Feb. 28, 2019	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2021	Jun. 30, 2019	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2019	Aug. 31, 2019
Refunds of revenues previously deferred								$ 337	$ 10,000
Deferred revenue, Long-term				$ 20,405				20,405					$ 21,318
Other assets				18,206				18,206					18,820
Deferred revenue				28,337	$ 32,373			28,337	32,373				28,722	$ 72,930
Deferred revenue, current portion				7,932				7,932					7,404
Total revenues				210,637	158,116			602,970	452,458
Deferred revenue, long-term portion				20,405				20,405					21,318
Revenue recognized during the period that was included in deferred revenues at the beginning of the period								7,877	32,864
Product
Revenue recognized				1,800	1,600			4,700	4,600
Cost of revenues				115,436	80,511			326,862	221,870
Total revenues				199,831	153,940			$ 584,415	413,971
Product | Minimum
Billing collection period (in months)								9 months
Product | Maximum
Billing collection period (in months)								12 months
Licensing and other
Cost of revenues				1,076	860			$ 2,102	2,426
Total revenues				10,806	$ 4,176			18,555	$ 38,487
Genetic testing services
Revenue recognized during the period that was included in deferred revenues at the beginning of the period								$ 3,300
Qiagen
Proceeds from license agreement											$ 5,000
Agreement term								10 years
Revenue, remaining performance obligation											40,000
Qiagen | Volume, regulatory and commercial milestones
Revenue, remaining performance obligation											$ 10,000
Qiagen | Other licensing and other revenue
Refunds of revenues previously deferred						$ 10,000
Deferred revenue						$ 28,600
Laboratory distribution partners | Product | Minimum
Billing collection period (in months)								2 months
Laboratory distribution partners | Product | Maximum
Billing collection period (in months)								3 months
BGI Genomics
Proceeds from license agreement			$ 50,000				$ 35,600
Receivable							$ 2,500
Agreement term			10 years
Deferred revenue, current portion				700				$ 700
BGI Genomics | Sequencing services
Other assets															$ 6,000
BGI Genomics | Sequencing products
Other assets															4,000
BGI Genomics | Sequencing products and services
Other assets															$ 10,000
BGI Genomics | Milestone payments
Receivable				4,500				4,500				$ 5,000
BGI Genomics | Milestone payments | Subsequent event
Revenue recognized	$ 4,500
Foundation Medicine ("FMI")
Proceeds from license agreement										$ 16,300
Foundation Medicine ("FMI") | Milestone payments
Proceeds from license agreement		$ 1,000
Receivable												$ 2,000
Deferred revenue, current portion				$ 1,000				$ 1,000					$ 2,000
Foundation Medicine ("FMI") | Upfront licensing fees and prepaid revenues
Initial transaction price																$ 13,300
Foundation Medicine ("FMI") | Developmental, regulatory, and commercial milestones
Initial transaction price																$ 32,000
Foundation Medicine ("FMI") | Developmental performance milestones
Proceeds from license agreement										3,000
Foundation Medicine ("FMI") | Licensing fees and prepaid revenue
Proceeds from license agreement										$ 13,300